Why Half of Tracked Drug Launches Still Underperform Pre-Launch Forecasts

Launching a new drug is one of the most expensive and high-stakes activities in the pharmaceutical industry. Yet, despite years of clinical research, market analysis, and commercial planning, roughly half of drug launches fail to reach their projected revenues.
The problem is rarely a single forecasting error. Drug launches unfold in a constantly changing environment where physician behavior, payer decisions, competitive actions, patient access, and field execution can shift after launch. A forecast that looks highly credible before launch can quickly lose relevance once real-world market behavior begins to emerge.
The bigger issue is that many organizations treat forecasting as a finished deliverable rather than an ongoing commercial management process.
The Forecast Is Not the Problem — The Assumptions Are
Every launch forecast depends on assumptions.
Companies estimate how quickly physicians will adopt a new therapy, how many patients will begin treatment, how insurers will cover the product, how competitors will respond, and how effectively sales and marketing teams will execute.
These assumptions may be reasonable when the forecast is created. But the market can change considerably between forecasting and launch.
That creates a fundamental challenge: the forecast can remain mathematically sound while becoming commercially outdated.

1. Physician Adoption Takes Time Not every physician changes prescribing behavior immediately. Some clinicians may adopt a new therapy quickly, while others wait for additional clinical experience, peer feedback, or stronger evidence before changing established prescribing habits. If a forecast assumes rapid adoption across the market, even a modest delay in physician uptake can create a significant gap between projected and actual prescriptions.
2. Market Access Can Disrupt Demand A drug can generate strong physician interest and still struggle to reach patients. Prior authorization requirements, coverage restrictions, approval processes, and high patient copays can create barriers between prescribing intent and treatment initiation. This distinction is critical. Low sales do not always indicate weak physician demand. Sometimes the problem is that patients cannot access the therapy after it has been prescribed.
3. Competitors Do Not Stand Still A launch forecast represents expectations about a competitive environment that may change rapidly. Competitors can introduce new promotional campaigns, change pricing, or secure additional indications. These actions can affect market share and alter the assumptions behind the original forecast. A forecast that does not continuously account for competitive activity can quickly become disconnected from market reality.
4. Commercial Teams May Not Be Fully Aligned Launch performance depends on coordination across sales, marketing, medical, and market access teams. When these functions operate around different priorities, messages, or objectives, execution can drift away from the assumptions built into the forecast. A strong forecast therefore requires more than an analytical model. It requires organizational alignment around the signals that determine launch performance.
5. Forecasting Becomes a One-Time Exercise Perhaps the most important issue is what happens after launch. Some organizations build a sophisticated forecast, use it to establish targets, and then rarely revisit the underlying assumptions. But actual prescription behavior, sales feedback, payer policies, and competitive conditions provide new information every week. Effective launch teams continuously update their forecasts using real-world evidence rather than relying on the original model indefinitely. From Static Forecasts to Dynamic Launch Management A successful launch does not depend on producing a perfect forecast before the product reaches the market. It depends on how quickly an organization can recognize when reality is diverging from expectations — and respond. This is where commercial data, pharmaceutical commercial analytics, and advanced analytics become strategically important. Strong teams continuously monitor market signals and adjust their assumptions as new evidence becomes available. Instead of asking only, “Are we hitting revenue targets?”, launch teams should be asking: Are physicians adopting the product at the expected rate? Are patients beginning treatment as projected? Are payer restrictions slowing access? Are prescriptions growing at the expected pace? Has competitor behavior changed? Are sales teams seeing something that the forecast does not capture? Which assumptions are beginning to break down? These questions turn forecasting into an active decision-making process. How Data and Analytics Improve Launch Forecast Accuracy Refresh Forecasts With Real-Time Data A forecast should evolve as the market provides new information. Prescription data, field intelligence, patient enrollment, and competitor activity can all provide signals that help teams reassess their assumptions. Rather than waiting for monthly or quarterly performance reviews, organizations can establish regular forecast-refresh cycles that identify changes early. Use More Sophisticated Forecasting Techniques Advanced forecasting systems can process substantially more information than traditional spreadsheets. Historical launch data, insurance information, clinical history, and digital engagement signals can be incorporated into analytical models. As more sales data becomes available, models can also be refined to reduce reliance on static assumptions and human judgment alone. The value is not simply greater mathematical sophistication. It is the ability to respond faster when market behavior changes. Improve Sales and Marketing Allocation Analytics can also help organizations determine where commercial investment is most likely to have an impact. For example, data can indicate which physicians need additional clinical information, which communication channels generate stronger engagement, and which geographic areas may require greater sales coverage. This allows commercial teams to move away from broad assumptions and toward more targeted resource allocation. The Metrics That Reveal What Is Really Happening Revenue is an important outcome, but it is often a lagging indicator. Leading launch teams track a broader collection of measures to understand why performance is moving in a particular direction. The source identifies several important launch metrics, including forecast accuracy, physician adoption, patient treatment starts, market share, insurance coverage, prescription volume, time to peak sales, and marketing engagement. Key Launch Metrics Forecast Accuracy: Measures how closely projections match actual sales. Doctor Adoption Rate: Shows how many physicians are actively prescribing the product. Patient Treatment Starts: Indicates how quickly patients are entering treatment. Market Share Growth: Helps evaluate competitive performance. Insurance Coverage: Reveals how easily patients can obtain coverage for the therapy. Prescription Volume: Tracks the actual number of prescriptions being filled. Time to Peak Sales: Shows how quickly the product approaches its maximum sales potential. Marketing Engagement: Identifies which sales and digital messages are generating meaningful engagement. Together, these indicators provide a more complete view of launch health than revenue alone. What Better Launch Management Looks Like Organizations that manage launches effectively treat forecasting as an iterative process. The source recommends several practices that can strengthen launch management, including continuous forecast updates, competitive monitoring, weekly tracking of physician prescribing and patient enrollment during the first six months, predictive risk models, cross-functional alignment, channel optimization, and greater emphasis on operational metrics. A practical launch framework therefore looks like this: Establish the initial forecast using the best available market and historical data. Define the leading indicators that will reveal whether the launch is progressing as expected. Monitor those indicators frequently after launch. Identify deviations early rather than waiting for revenue misses. Diagnose the cause — whether it is physician adoption, patient access, competition, execution, or another factor. Update the forecast and commercial strategy. Repeat the process continuously. This creates a feedback loop between market reality and commercial decision-making. How Perceptive Analytics Supports Smarter Launch Forecasting Perceptive Analytics approaches launch forecasting as an ongoing process rather than a static planning exercise. Its approach combines forecasting, prescription data, market intelligence, dashboards, predictive analytics, and industry expertise to help commercial teams monitor launch performance and adjust assumptions as conditions evolve. Forecast Development and Validation Forecasting models can incorporate patient populations, previous launch data, market research, and sales assumptions. These models can then be regularly validated against actual performance. Commercial Performance Dashboards Launch dashboards can bring key indicators into one view, including forecast accuracy, prescription volume, physician adoption, patient starts, market share, insurance penetration, and sales-force performance. Real-World Data Integration Combining prescription trends, insurance claims, patient-journey information, competitor behavior, insurance penetration, and field feedback can provide a more complete picture of launch performance. Predictive and AI-Driven Analytics Predictive models can help identify demand shifts, detect deviations from targets, and highlight potential market risks before they materially affect performance. Market Access Analysis Insurance approvals, copay tiers, prior authorization requirements, and coverage restrictions can be monitored to understand how access barriers affect patient uptake. Commercial Optimization Patterns in sales data can help teams make more informed decisions about physician targeting, territory design, and marketing investment. Continuous Forecast Refresh Most importantly, the forecast does not remain fixed. New sales data and market developments can be incorporated continuously so that decision-makers are working with the most current view of expected performance. A Real-World Example: When Low Prescriptions Were Not a Physician Problem The source describes a specialty pharmaceutical company whose prescription levels were 25% below expectations during the first eight weeks after launch. At first glance, the performance suggested weaker physician interest. However, deeper commercial analysis identified a different problem: prior authorization barriers across several large payer plans. The company responded by changing its market access strategy and refreshing its launch assumptions weekly during the first six months. The lesson is important: a revenue or prescription gap tells you that something is wrong; analytics can help determine what is actually causing it. The Bigger Lesson for Pharma Launches A drug launch forecast should never be treated as a final answer. It is a starting hypothesis about how the market will behave. Once the product launches, real-world data begins to challenge or validate that hypothesis. Physicians reveal their actual prescribing behavior. Patients reveal treatment-start patterns. Payers expose access barriers. Competitors respond. Sales teams provide field intelligence. The organizations that perform best are those that absorb these signals quickly and adjust. This is where pharma commercial analytics can play a central role — connecting market signals, commercial performance, and operational data so that teams can move from simply measuring a launch to actively managing it. Conclusion Half of tracked drug launches underperform their pre-launch revenue expectations not necessarily because companies cannot forecast. The deeper challenge is that markets change faster than static forecasts can accommodate. Physician adoption may take longer. Payer restrictions may limit access. Competitors may change their strategies. Patients may behave differently from expectations. Internal execution may also diverge from the original plan. The answer is not to abandon forecasting. It is to make forecasting dynamic. Organizations should monitor leading indicators, refresh assumptions continuously, connect sales and market data, and align commercial, medical, and market access teams around shared objectives. A successful launch is therefore not defined by how accurate the original forecast was. It is defined by how quickly the organization learns from reality and adapts its strategy. That shift from static prediction to continuous commercial intelligence can make the difference between a launch that merely meets expectations and one that reaches its full market potential.